The company is using a recently closed funding round to drive commercialization of the test, which measures three proteins in urine to detect pancreatic cancer.

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in the brain.

Siemens Healthineers will leverage its regional network and healthcare technology expertise to support the adoption of Aiforia's pathology tools.

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

The new swab technology allows for non-invasive collection of patient samples without the need for liquids or complex devices.

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.

NEW YORK – The US Food and Drug Administration in September granted 510(k) marketing clearances for tests to aid the identification of bacterial infections, determine the susceptibility of infectious ...